| --- | --- | --- | --- | |-----------------|-------|----------|-------| | | | | | | | | | | | Dexcom | | | | | Dexcom earnings | | ny faces | | | Q3 2024 | | Nasdag | | | | | | | | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Table of Contents DEXCOM, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisd ...

Shares of Dexcom fell 9% in extended trading on Thursday after the company released third-quarter results that beat analysts' expectations but showed a decline in U.S. revenue year over year.Here's how the company did:Earnings per share: 45 cents adjusted vs. 43 cents expected by LSEGRevenue:  $994 million vs. $990 million expected by LSEGThe company's revenue increased 2% to $994.2 million from $975 million a year earlier. Dexcom's U.S. revenue declined 2% from $713.6 million the prior year. The company re ...

Exhibit 99.1 Dexcom Reports Third Quarter 2024 Financial Results SAN DIEGO - (BUSINESS WIRE-October 24, 2024) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: 1 • Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic basis. • U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic basis, all on a year-o ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against DexCom, Inc. regarding a class action complaint filed due to alleged breaches of fiduciary duties by the board of directors [1] Financial Performance - On July 25, 2024, DexCom announced its Q2 fiscal 2024 financial results and reduced its revenue guidance for the full fiscal year 2024, attributing the results to the execution of several key strategic initiatives that did not meet their standards [2] - Following the announcement, DexCom's stock price plummeted from $107.85 per share on July 25, 2024, to $64.00 per share on July 26, 2024, marking a decline of approximately 40.66% in just one day [2]

DexCom, Inc. (DXCM) is scheduled to release third-quarter 2024 results on Oct. 24, after the closing bell. In the last reported quarter, the company’s earnings beat estimates by 10.26%.The bottom line also outpaced the consensus mark in each of the trailing four quarters, delivering an average surprise of 23.03%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the Zacks Consensus Estimate for revenues is pegged at $991.6 million, indicating growth of 1.7% from ...

Core Insights - DexCom (DXCM) is expected to report quarterly earnings of $0.43 per share, a decline of 14% year-over-year, with revenues forecasted at $991.55 million, reflecting a 1.7% increase compared to the previous year [1] - The consensus EPS estimate has been adjusted downward by 0.4% over the past 30 days, indicating a reassessment by analysts [1] Revenue Estimates - Analysts predict 'Revenue- Hardware' will reach $49.44 million, representing a significant decline of 51.2% from the year-ago quarter [2] - 'Revenue- Sensor and other' is expected to be $941.35 million, indicating a year-over-year increase of 7.7% [2] - 'Revenue- United States' is forecasted to be $719.01 million, reflecting a slight increase of 0.8% from the previous year [2] - 'Revenue- International' is estimated to reach $265.16 million, showing a year-over-year growth of 1.4% [3] Stock Performance - DexCom shares have increased by 2.8% over the past month, while the Zacks S&P 500 composite has moved up by 4.5% [3] - With a Zacks Rank 4 (Sell), DexCom is anticipated to underperform the overall market in the near future [3]

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO ...

Core Viewpoint - A securities class action lawsuit has been filed against DexCom, Inc. for allegedly misleading investors regarding its sales force expansion strategy and its impact on customer growth and market share [1][2]. Group 1: Allegations Against DexCom - The lawsuit claims that DexCom's sales force expansion strategy led to slow customer growth [2] - It is alleged that this strategy undermined relationships with durable medical equipment (DME) distributors, which are crucial for revenue generation [2] - The deteriorating relationships with DME distributors reportedly caused DexCom to lose significant market share to competitors [2] - As a result of these issues, statements made by DexCom during the Class Period about its business and operations were deemed false and misleading [2] Group 2: Lead Plaintiff Process - Investors in DexCom have until October 21, 2024, to seek appointment as a lead plaintiff representative in the class action [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The lead plaintiff selects counsel to represent the class, and this decision does not affect the ability of other investors to share in any recovery [3] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4][5] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [5]